Research - Cellectis/treating physicians will discuss the first-in-human experience with UCART19, the company's allogeneic CD-19 targeted CAR-T asset, at ASH. And, they may be able to discuss results in more than one patient.
Premium: Read NowResearch - The recovery is slowly underway in the land of biotech, and these equities are getting a lift from Pfizer's (PFE) planned merger with Allergan (AGN), announced Monday.
Read NowResearch - Bellicum Pharmaceuticals (BLCM) after the bell this evening reported third quarter earnings, but more importantly noted that four pediatric beta-thalassemia patients who underwent HSCT followed by BPX-501 modified T cells are transfusion-free.
Premium: Read NowResearch - ASH 2015 abstracts are available publicly this morning (browse them here), and biotech had a rough morning.
Premium: Read NowResearch - Bellicum is a cell therapy developer with a pipeline of early therapeutics, including the now-ubiquitous chimeric antigen receptor T cell candidates (a la Juno Therapeutics (JUNO) and Kite (KITE)) and T cell receptor (TCR) candidates, neither of which will enter the clinic until next year.
Premium: Read NowResearch - These events set 1H16 up as a make-or-break period for Marinus. The company has enough cash ($34.5 million at September 30) to get through 2016
Premium: Read NowResearch - The breakout we’ve been looking for from the biotech sector (NASDAQ’s Biotech Index Fund (IBB) is underway coming out of large-cap bio and pharma earnings over the last two days. Beats across the board have investors enthused – at least for now – about the sector as a whole.
Premium: Read Now
